Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
17 December 1986Website:
http://www.axogeninc.comNext earnings report:
07 November 2024Last dividends:
27 January 2010Next dividends:
N/APrice
after hours | Fri, 01 Nov 2024 20:18:08 GMTDividend
Analysts recommendations
Institutional Ownership
AXGN Latest News
AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Bioventus, Great Lakes Dredge & Dock, and AxoGen have been selected as the breakout stocks for today.
ALACHUA, Fla. and TAMPA, Fla., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that it has completed the rolling submission process for its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®.
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AxoGen (AXGN) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to loss of $0.03 per share a year ago.
ALACHUA, Fla. and TAMPA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Michael Dale is appointed as chief executive officer and as a member of the Axogen Board of Directors effective August 9, 2024. He succeeds Karen Zaderej, who will remain in an advisory role for nine months.
AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AxoGen (AXGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
AxoGen (AXGN) announces the full launch of its Avive+ Soft Tissue Matrix to provide comprehensive solutions for nerve protection.
- 1(current)
What type of business is AxoGen?
AxoGen, Inc. is a medical technology company specializing in the development and commercialization of technologies for the regeneration and restoration of peripheral nerves. It was founded in 2002. The company's headquarters are located in Alachua, Florida, USA. The company creates nerve connectors, soft tissue membranes, and also uses the AVANCE cellular transplant technology to mimic the human nerve. The company's products are used for treating a wide range of peripheral nerve injuries by plastic surgeons, orthopedic surgeons, maxillofacial surgeons, and others. Axogen, Inc. owns or is the exclusive licensee of around 20 US patents and approximately 70 international patents, with about 15 US patent applications pending.
What sector is AxoGen in?
AxoGen is in the Healthcare sector
What industry is AxoGen in?
AxoGen is in the Medical Devices industry
What country is AxoGen from?
AxoGen is headquartered in United States
When did AxoGen go public?
AxoGen initial public offering (IPO) was on 17 December 1986
What is AxoGen website?
https://www.axogeninc.com
Is AxoGen in the S&P 500?
No, AxoGen is not included in the S&P 500 index
Is AxoGen in the NASDAQ 100?
No, AxoGen is not included in the NASDAQ 100 index
Is AxoGen in the Dow Jones?
No, AxoGen is not included in the Dow Jones index
When was AxoGen the previous earnings report?
No data
When does AxoGen earnings report?
The next expected earnings date for AxoGen is 07 November 2024